Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

C. Soussain (1) , S. Choquet (2) , M. Blonski , D. Leclercq (2) , C. Houillier (2) , K. Rezai (1) , F. Bijou (3) , R. Houot (4) , E. Boyle , R. Gressin , E. Nicolas-Virelizier (5) , M. Barrie (6) , C. Moluçon-Chabrot , M.L. Lelez , A. Clavert , S. Coisy , S. Leruez , V. Touitou , N. Cassoux (1) , M. Daniau (7) , M. Ertault de La Bretonnière (8) , A. El Yamani , H. Ghesquières (9) , K. Hoang-Xuan

1 Institut Curie [Paris]
2 CHU Pitié-Salpêtrière [AP-HP]
3 Institut Bergonié [Bordeaux]
4 MICMAC - Microenvironment, Cell Differentiation, Immunology and Cancer
5 Centre Léon Bérard [Lyon]
6 TIMONE - Hôpital de la Timone [CHU - APHM]
7 EMBL - European Molecular Biology Laboratory [Grenoble]
8 CHU - Hôpital Lapeyronie [Montpellier]
9 UCBL - Université Claude Bernard Lyon 1

Keywords: Relapse; Primary CNS lymphoma; Primary vitreoretinal lymphoma; Ibrutinib

Domains: Cancer

C. Soussain, S. Choquet, M. Blonski, D. Leclercq, C. Houillier, et al.. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. European Journal of Cancer, 2019, 117, pp.121-130. ⟨10.1016/j.ejca.2019.05.024⟩. ⟨hal-02182035⟩